Blood plasma/IgG N-glycome biosignatures associated with major depressive 
disorder symptom severity and the antidepressant response

Park, Dong Ik; Stambuk, Jerko; Razdorov, Genadij; Pucic-Bakovic, Maja; Martins-de-Souza, Daniel; Lauc, Gordan; Turck, Christoph W.

doi:10.1038/s41598-017-17500-0

Item

ITEM ACTIONSEXPORT

Add to Basket

Release HistoryDetailsSummary

Released

Journal Article

Blood plasma/IgG N-glycome biosignatures associated with major depressive disorder symptom severity and the antidepressant response

MPS-Authors

/persons/resource/persons202082

Park, Dong Ik
Dept. Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80561

Turck, Christoph W.
RG Proteomics and Biomarkers, Dept. Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

Blood plasma IgG N-glycome biosignatures_s41598-017-17500-0.pdf
(Publisher version), 5MB

Supplementary Material (public)

There is no public supplementary material available

Citation

Park, D. I., Stambuk, J., Razdorov, G., Pucic-Bakovic, M., Martins-de-Souza, D., Lauc, G., et al. (2018). Blood plasma/IgG N-glycome biosignatures associated with major depressive disorder symptom severity and the antidepressant response. SCIENTIFIC REPORTS, 8: 179. doi:10.1038/s41598-017-17500-0.

Cite as: https://hdl.handle.net/21.11116/0000-0002-73C9-A

Abstract

While N-linked glycosylation has been extensively studied in the context of inflammatory and metabolic disorders, its relationship with major depressive disorder (MDD) and antidepressant treatment response has not been investigated. In our exploratory study, we analysed N-glycan profiles in blood plasma samples collected from MDD patients (n = 18) and found gender-dependent correlations with severity of depressive symptoms prior to initiating antidepressant treatment. In addition, several N-glycosylation traits showed gender-dependent associations with clinical antidepressant response. Follow up proteomics analysis in peripheral blood mononuclear cells (PBMCs) collected from MDD patients (n = 20) identified baseline and post-antidepressant treatment pathway differences between responder and non-responder patients. Reactome data analysis further delineated potential biological reaction differences between responder and non-responder patients. Our preliminary results suggest that specific glycosylation traits are associated with depressive symptom severity and antidepressant response and may be of use as biomarkers.